Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low – Here’s Why

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report)’s share price hit a new 52-week low during trading on Monday. The stock traded as low as $12.01 and last traded at $12.6040, with a volume of 1,698,713 shares trading hands. The stock had previously closed at $14.15.

Summit Therapeutics News Roundup

Here’s some of the latest news about SMMT:

Wall Street Analyst Weigh In

SMMT has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. UBS Group reaffirmed a “neutral” rating on shares of Summit Therapeutics in a research note on Wednesday, September 23rd. Summit Redstone set a $25.00 price objective on Summit Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Finally, Citigroup reissued a “market outperform” rating on shares of Summit Therapeutics in a research note on Tuesday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.61.

Get Our Latest Stock Analysis on Summit Therapeutics

Summit Therapeutics Price Performance

The business’s 50-day moving average is $16.41 and its two-hundred day moving average is $16.14. The firm has a market cap of $10.28 billion, a P/E ratio of -11.99 and a beta of -1.49.

Institutional Trading of Summit Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SMMT. Fifth Third Bancorp raised its position in shares of Summit Therapeutics by 24.4% in the first quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock valued at $71,000 after buying an additional 732 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Summit Therapeutics by 0.7% in the second quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock valued at $1,764,000 after buying an additional 783 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Summit Therapeutics by 2.4% in the third quarter. Russell Investments Group Ltd. now owns 42,714 shares of the company’s stock valued at $722,000 after buying an additional 1,021 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of Summit Therapeutics by 1.1% in the third quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock valued at $1,611,000 after buying an additional 1,025 shares during the period. Finally, GAMMA Investing LLC grew its position in Summit Therapeutics by 61.7% during the third quarter. GAMMA Investing LLC now owns 2,697 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares in the last quarter. Institutional investors own 4.61% of the company’s stock.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

Featured Articles

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.